Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
暂无分享,去创建一个
F. Saad | D. Penson | B. Tombal | C. Sternberg | C. Ivanescu | M. Hussain | K. Ramaswamy | G. Attard | R. Morlock